ArticleScientific reports2026
Mesenchymal to epithelial transition (MET) in cancer progression: insights from logical modeling.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Systems-level analysis identifies IRF6 as an inhibitor of epithelial-mesenchymal transition.Journal of biological engineering · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The ability of carcinoma cells to transition along the epithelial-mesenchymal spectrum is crucial for metastasis. While the process of Epithelial to Mesenchymal Transition (EMT) has widely been studied, its reverse, Mesenchymal to Epithelial Transition (MET), has been less thoroughly explored. Here, we first present a comprehensive overview of the known MET inducers in cancer, detailing the cellular contexts in which they play a role and their interactions with EMT drivers. Based on these observations, we constructed a minimal regulatory network centered on key signaling pathways, including Transforming Growth Factor β (TGFβ), Bone morphogenetic protein (BMP), and other growth factors. This network was then translated into a logical model to explore the dynamic interplay between EMT and MET programs. Through in silico simulations, we demonstrate how perturbing this network can interfere with EMT programs to induce MET. Our findings highlight that the MET process is highly dependent on the mesenchymal context. We further demonstrate that persistence of EMT programs constrains how far along the epithelial–mesenchymal spectrum different MET inducers can reposition mesenchymal cells. Moreover, perturbing components of one EMT program can reinforce alternative EMT pathways, thereby preserving this balance and preventing a full reversion to epithelial states, highlighting a new function for cells with hybrid states.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.